IL-35对慢加急性肝衰竭患者外周血CD8+ T淋巴细胞功能的影响

高艺; 梁志军; 符健

doi:10.3969/j.issn.1001-5256.2019.09.025

IL-35对慢加急性肝衰竭患者外周血CD8+ T淋巴细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2019.09.025

1. 海南省人民医院感染科

详细信息

中图分类号: R575.3
计量
- 文章访问数: 518
- HTML全文浏览量: 83
- PDF下载量: 110
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-27
- 出版日期: 2019-09-20

Influence of interleukin-35 on peripheral CD8+ T cell function in patients with acute-on-chronic liver failure

Department of Infectious Diseases, Hainan Provincial People's Hospital

摘要

摘要:
目的观察慢加急性肝衰竭（ACLF）患者血清IL-35表达水平,评估IL-35对ACLF患者CD8+T淋巴细胞功能的影响。方法纳入2018年11月-2019年4月在海南省人民医院就诊的ACLF患者28例和健康对照者14例,采用ELISA法检测血清IL-35水平。分选外周血CD8+T淋巴细胞,使用重组人IL-35刺激培养,应用实时定量PCR法检测CD8+T淋巴细胞中穿孔素、颗粒酶B和颗粒溶素mRNA水平,流式细胞术检测CD8+T淋巴细胞中程序性死亡分子-1（PD-1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）的表达。应用直接接触和间接接触共培养系统将HLA-A2限制性CD8+T淋巴细胞与HepG2细胞共培养,加入重组人IL-35后通过检测靶细胞死亡比率和细胞因子分泌评估CD8+T淋巴细胞的细胞毒性和非细胞毒性功能的变化。符合正态分布的计量资料2组间比较采用两独立样本t检验或配对t检验;不符合正态分布的计量资料2组间比较采用Mann-Whitney U检验;相关性分析采用Spearman秩相关分析。结果 ACLF患者血清IL-35水平[72. 32（54. 04～111. 30） pg/...
- 慢加急性肝功能衰竭 /
- 白细胞介素35 /
- CD8阳性T淋巴细胞
Abstract:
Objective To investigate the serum level of interleukin-35 ( IL-35) and its influence on CD8+T cell function in patients with acute-on-chronic liver failure ( ACLF) . Methods A total of 28 patients with ACLF who attended Hainan Provincial People's Hospital from November 2018 to April 2019 and 14 healthy controls were enrolled in this study. ELISA was used to measure the serum level of IL-35. Peripheral CD8+T cells were separated and stimulated with recombinant human IL-35, and real-time quantitative PCR was used to measure the mRNA expression of perforin, granzyme B, and granulysin in CD8+T cells; flow cytometry was used to measure the expression of programmed death-1 ( PD-1) and cytotoxic T-lymphocyte-associated antigen 4 ( CTLA-4) in CD8+T cells. The direct-and indirect-contact co-culture systems were used for the co-culture of HLA-A2-restricted CD8+T cells and HepG2 cells, and after recombinant human IL-35 was added, the percentage of target cell death and the secretion of cytokines were measured to evaluate the changes in the cytolytic and noncytolytic activities of CD8+T cells. The two-independent-samples t test or the paired t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the Spearman correlation analysis was performed to investigate correlation. Results Compared with the health controls, the patients with ACLF had a significant increase in the serum level of IL-35 [72. 32 ( 54. 04-111. 30) pg/ml vs 46. 00 ( 27. 02-82. 29) pg/ml, Z = 2. 184, P = 0. 020]. CD8+T cell exhaustion was observed in ACLF patients, with the manifestations of reductions in the relative mRNA expression of perforin and granzyme B, increases in the percentages of PD-1+or CTLA-4+CD8+T cells, and reductions in the cytolytic ( induction of target cell death) and noncytolytic ( secretion of interferon-γ) functions of CD8+T cells ( all P < 0. 05) . After the stimulation with recombinant IL-35, both ACLF patients and healthy controls had significant reductions in the relative mRNA expression of perforin and granzyme B in CD8+T cells, significant increases in the percentages of PD-1+orCTLA-4+CD8+T cells, and significant reductions in the cytolytic and noncytolytic functions of CD8+T cells ( all P < 0. 05) . Conclusion Elevated IL-35 can suppress the cytolytic activity of CD8+T cells in ACLF patients, suggesting that IL-35 might induce the exhaustion of cellular immune function in ACLF patients.
- acute-on-chronic liver failure /
- interleukin-35 /
- CD8-positive T-lymphocytes

HTML全文

参考文献(16)

[1] HAN Y, CUI LN, GUO GY. Immunotherapy for acute-onchronic liver failure[J]. J Clin Hepatol, 2017, 33 (9) :1677-1682. (in Chinese) 韩英, 崔丽娜, 郭冠亚.慢加急性肝衰竭的免疫治疗[J].临床肝胆病杂志, 2017, 33 (9) :1677-1682.

[2] TEYMOURI M, PIRRO M, FALLARINO F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases[J]. Int J Cancer, 2018, 143 (9) :2105-2115.

[3] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018) [J]. J Clin Hepatol, 2019, 35 (1) :38-44. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2018年版) [J].临床肝胆病杂志, 2019, 35 (1) :38-44.

[4] LI Y, ZHANG H, LI Z, et al. Influence of the Notch signaling pathway on CD8+T lymphocyte function in patients with chronic hepatitis C[J]. J Clin Hepatol, 2018, 34 (2) :287-291. (in Chinese) 李彧, 张鸿, 李竹, 等. Notch信号通路对慢性丙型肝炎患者CD8+T淋巴细胞功能的影响[J].临床肝胆病杂志, 2018, 34 (2) :287-291.

[5] WANG HM, ZHANG XH, FENG MM, et al. Interleukin-35suppresses the antitumor activity of T cells in patients with non-small cell lung cancer[J]. Cell Physiol Biochem, 2018, 47 (6) :2407-2419.

[6] ZHANG J, ZHANG Y, WANG Q, et al. Interleukin-35 in immune-related diseases:Protection or destruction[J]. Immunology, 2019, 157 (1) :13-20.

[7] DAMO M, JOSHI NS. Treg cell IL-10 and IL-35 exhaust CD8+T cells in tumors[J]. Nat Immunol, 2019, 20 (6) :674-675.

[8] TENG DK, LIU Y, LV YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection[J]. Int Immunopharmacol, 2019, 70:252-259.

[9] SHAO X, MA J, JIA S, et al. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection[J]. Front Cell Infect Microbiol, 2017, 7:472.

[10] LIU S, ZHANG Q, SHAO X, et al. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection[J]. Int Immunopharmacol, 2017, 50:87-94.

[11] FU YP, YI Y, CAI XY, et al. Overexpression of interleukin-35associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection[J]. Br J Cancer, 2016, 114 (7) :767-776.

[12] CHEN L, LUO EP, HUANG XP, et al. Expression of IL-35 in patients with acute-on-chronic liver failure and its clinical significances[J]. J Practical Med, 2013, 29 (17) :2800-2802. (in Chinese) 陈丽, 罗二平, 黄小平, 等.乙型慢加亚急性肝衰竭患者血清白细胞介素-35的表达及其临床意义[J].实用医学杂志, 2013, 29 (17) :2800-2802.

[13] DURGEAU A, VIRK Y, CORGNAC S, et al. Recent advances in targeting CD8 T-Cell immunity for more effective cancer immunotherapy[J]. Front Immunol, 2018, 9:14.

[14] LIU MX, LIU QY, LIU Y, et al. Interleukin-35 suppresses antitumor activity of circulating CD8+T cells in osteosarcoma patients[J]. Connect Tissue Res, 2019, 60 (4) :367-375.

[15] ZHENG XF, HU XY, FANG H, et al. Interleukin-35 attenuates D-galactosamine/lipopolysaccharide-induced liver injury via enhancing interleukin-10 production in Kupffer cells[J].Front Pharmacol, 2018, 9:959.

[16] WANG W, GUO H, LI H, et al. Interleukin-35 gene-modified mesenchymal stem cells protect concanavalin a-induced fulminant hepatitis by decreasing the interferon gamma level[J]. Hum Gene Ther, 2018, 29 (2) :234-241.

施引文献

资源附件(0)

访问统计